Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Hansa Biopharma AB (publ) is a commercial-stage biopharmaceutical company focused on pioneering the development and commercialization of innovative immunomodulatory treatments for patients with rare immunological conditions. Founded in 2007 and headquartered in Lund, Sweden, the company leverages a proprietary antibody-cleaving enzyme technology platform to target pathogenic IgG antibodies. Its lead product, imlifidase, has received conditional marketing authorization in the European Union as Idefirix for desensitization in highly sensitized adult kidney transplant patients and is advancing toward potential US approval via a Biologic License Application to the FDA. The pipeline includes next-generation enzyme HNSA-5487 and explorations in indications like anti-GBM disease, gene therapy pre-treatments for Duchenne muscular dystrophy with Sarepta Therapeutics, Crigler-Najjar syndrome with Généthon, and others. With 11 clinical and preclinical programs, Hansa Biopharma operates subsidiaries across Europe, the US, and Australia, emphasizing patient-centric innovation, sustainability, diversity, and a workforce representing over 30 nationalities. This positions it as a key player in addressing unmet needs in transplantation, autoimmune diseases, and gene therapy.
kr 2.96
+kr 0.14 (+5.04%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-232.96% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 29.7% YoY with margins expanding 135.7pp.
Negative free cash flow of -kr 549M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 190M
▲ +29.7% YoY
Net Income (TTM)
-kr 692M
▲ +33.8% YoY
Op. Margin
-297.61%
▲ +135.7pp YoY
ROIC
-40.55%
▲ +10.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 554M
▲ +18.6% YoY
Op. Cash Flow (TTM)
-kr 667M
▲ +8.8% YoY
Net Debt
kr 238M
Cash & Equiv.
kr 701M
3Y CAGR: +12.9%
Continue Research
Hansa Biopharma AB (publ) (HNSA.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Hansa Biopharma AB (publ) scores 26/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Hansa Biopharma AB (publ) scores 26 out of 100 on Intrinsiqq's quality score, passing 1 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -297.6% operating margin and a -40.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh HNSA.XSTO's valuation and scores 26/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.